Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole

Conclusions:
Administration of dexlansoprazole 30 mg ODT or 30 mg capsule provided equivalent plasma exposure when either was administered as a single dose or as once daily doses for 5 days. Pharmacodynamic equivalence between the two formulations was demonstrated by similar intragastric pH parameters on both day 1 and day 5. No effect of day on dexlansoprazole pharmacokinetics was observed. Dexlansoprazole ODT and dexlansoprazole capsule were both well tolerated.

Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Kukulka, M., Nudurupati, S., Perez, M. C. Tags: Original Research Source Type: research